Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chong Kun Dang Pharmaceutical Corp.

http://www.ckdpharm.com/en/home

Latest From Chong Kun Dang Pharmaceutical Corp.

Korean Pharmas Race To Globalize But Tacks Vary

Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.

South Korea Business Strategies

Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.

Coronavirus COVID-19 BioPharmaceutical

Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

Coronavirus COVID-19 Clinical Trials

Korea Botox Rivalry To Intensify After Meditoxin Measures

As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.

South Korea Biologics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register